• NEBANNER

Rivaroxaban (S)-Rivaroxaban;BAY 59-7939;RivaroxabanIsomer;Rivaroxaban;

Rivaroxaban (S)-Rivaroxaban;BAY 59-7939;RivaroxabanIsomer;Rivaroxaban;

Takaitaccen Bayani:

Tsarin kwayoyin halitta: C19H18ClN3O5S

Nauyin kwayoyin halitta: 435.88

CAS no: 366789-02-8


Cikakken Bayani

Tags samfurin

Aikace-aikace

An yi amfani da shi a cikin manya marasa lafiya tare da zaɓaɓɓen hip ko aikin maye gurbin gwiwa don hana thrombosis venous (VTE).

Ana amfani da shi don hana ko rage samuwar thrombosis, thrombosis mai zurfi (DVT) da kuma ciwon huhu (PE) bayan tiyata na maye gurbin hip ko gwiwa.

Adadin da aka ba da shawarar shine rivaroxaban na baka 10mg, sau ɗaya a rana.Ana iya ɗaukar Rivaroxaban 10mg tare da abinci ko kadai.Rivaroxaban 15mg ko 20mg Allunan yakamata a sha tare da abinci.

misali: usp40
Matsakaicin: 99-102%

Na waje: Farin foda
Kunshin: 25kg/drum

Raw abu miyagun ƙwayoyi kira tsari

Dauki 4- (4-aminophenyl) morpholin-3-daya (SM-1), (S) -N-glycidyl phthalimide (SM-2), 5-chlorothiophene-2- Formyl chloride (SM-3) shine farkon abu. .Bayan dasawa, hawan keke, aminolysis da acylation, ana samun danyen rivaroxaban, kuma an tsabtace rivaroxaban da aka gama.
Shiri: Wannan samfur jan kwamfutar hannu ce mai rufin fim.

Na'urorin haɗi:
Tablet core: microcrystalline cellulose, croscarmellose sodium, lactose monohydrate, hypromellose, sodium lauryl sulfate, magnesium stearate.
Rufi: polyethylene glycol, hypromellose, titanium dioxide, baƙin ƙarfe oxide ja

Pharmacological effects

Rivaroxaban magani ne mai zaɓin gaske, na baka wanda ke hana factor Xa kai tsaye.Ta hanyar babban zaɓi da gasa hanawa na kyauta da ɗaure factor Xa da ayyukan prothrombin, tsawaita lokacin farantin lokaci na thromboplastin da aka kunna (PT) da lokacin prothrombin (aPTT) ta hanyar dogaro da kashi, wanda zai iya katse magudanar ruwa na coagulation The endogenous and exogenous hanyoyin hana samar da thrombin da thrombosis.Rivaroxaban baya hana thrombin (factor kunnawa Ⅱ), kuma bai tabbatar da yin tasiri akan platelet ba.
Bambanci mai mahimmanci tsakanin rivaroxaban da fondaparinux / heparin shine cewa baya buƙatar sa hannu na antithrombin III kuma yana iya yin adawa da kai tsaye da kuma ɗaure factor Xa;yayin da heparin yana buƙatar antithrombin III don aiki, kuma Ba shi da wani tasiri akan factor Xa a cikin hadaddun prothrombin.

Layin Samfuri mai haɗaka da albarkatu

wps_doc_0

Takaddun shaida

JIN DUN Medical yaCancantar ISO kuma ya cika ka'idodin samar da GMP, ƙwararrun ƙwararrun haɗaɗɗun ƙwayoyi na cikin gida da na waje tare da ƙwararrun ƙwarewa don jagorantar R&D na kamfani.

13
d68590fe
12
111

Abũbuwan amfãni a kan Gyaran Likita

TECHNOL OGY AMFANIN
●High Matsi Catalytic Hydrogenation.Babban Matsi na Hydrogenolysis Reaction.Maganin Cryogenic (<-78% C)
●Aromatic Heterocyclic Synthesis
●Maganar Sake Shiryawa
●Matsalar Chiral
●Heck, Suzuki,Negishi,Sonogashira .Gignard Reaction

JIN DUN R&D

Kayan aiki

Our Lab yana da daban-daban na gwaji da kuma gwaji kayan aiki, kamar: NMR (Bruker 400M), HPC, Chiral-HPLC, LC-MS, LC-MS/MS (API 4000) , IR, UV, GC, GC-MS, Chromatography, Microwave Synthesizer, Parallel Synthesizer, Bambance-bambancen Scanning Calorimeter (DSC), Electron Microscope...

Ƙungiyar R&D

Jindun Medical yana da rukuni na ƙwararrun ma'aikatan R&D, kuma yana ɗaukar ƙwararrun masana harhada magunguna na cikin gida da na waje don jagorantar R&D, yana sa ƙirarmu ta fi dacewa da inganci.

wps_doc_3

Raba Harka

Mun taimaka wa manyan kamfanonin harhada magunguna na cikin gida da yawa, kamarHansoh, Hengrui da HEC Pharm.Anan zamu nuna sashinsu.

wps_doc_4

Hali na Farko na Farko:

Lambar Waya: 110351-94-5

wps_doc_5

Hali na Musamman na Biyu:

Lambar Waya: 144848-24-8

wps_doc_6

Halin Hali na Uku:

Lambar Waya: 200636-54-0

Yanayin Haɗin kai

1.Keɓance Sabbin Matsakaici ko APIs.Daidai da raba shari'ar na sama, abokan ciniki suna da buƙatun takamaiman Matsakaici ko APIs, kuma ba za su iya samun samfuran da ake buƙata ba a kasuwa, sannan za mu iya taimakawa don Keɓancewa.

2.Haɓaka Tsari don Tsofaffin Kayayyaki.Ƙungiyarmu za ta taimaka don ingantawa da haɓaka irin wannan samarwa wanda hanyar amsawa ta tsufa, farashin samarwa yana da yawa, kuma ingancin ya yi ƙasa.Za mu iya samar da cikakkun takardun shaida don canja wurin fasaha da haɓaka tsari, taimakawa abokin ciniki don samar da ingantaccen aiki.

Daga maƙasudin miyagun ƙwayoyi zuwa INDs, JIN DUN Medical yana ba kumafita na R&D keɓaɓɓen tsayawa ɗaya tasha.

JIN DUN Medical ya dage kan ƙirƙirar ƙungiyar tare da mafarkai, yin samfura masu daraja, ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwaƙƙwaran, masu tsattsauran ra'ayoyi, masu tsauri, da kuma fita gabaɗaya don zama amintaccen abokin tarayya kuma abokin abokan ciniki!


  • Na baya:
  • Na gaba:

  • Ku rubuta sakonku anan ku aiko mana